MARKET

CADL

CADL

Candel Therapeutics, Inc.
NASDAQ
8.77
-0.14
-1.57%
After Hours: 8.94 +0.17 +1.94% 19:59 05/15 EDT
OPEN
8.67
PREV CLOSE
8.91
HIGH
9.07
LOW
7.78
VOLUME
3.68M
TURNOVER
--
52 WEEK HIGH
9.27
52 WEEK LOW
4.350
MARKET CAP
642.58M
P/E (TTM)
-8.9709
1D
5D
1M
3M
1Y
5Y
1D
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
TipRanks · 21h ago
Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual Meeting
Benzinga · 23h ago
Candel says CAN-2409 cuts prostate cancer recurrence risk 39% in Phase 3 follow-up
PUBT · 23h ago
CANDEL THERAPEUTICS REPORTS EXTENDED CLINICAL BENEFIT OVER MULTIPLE CLINICAL ENDPOINTS IN PATIENTS FROM PHASE 3 TRIAL OF AGLATIMAGENE BESADENOVEC (CAN-2409) IN LOCALIZED PROSTATE CANCER UNDER PROLONGED FOLLOW-UP AT AUA 2026 ANNUAL MEETING
Reuters · 23h ago
Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Pyxis Oncology (PYXS) and Candel Therapeutics (CADL)
TipRanks · 1d ago
Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors
PUBT · 1d ago
Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Azitra Inc (AZTR)
TipRanks · 2d ago
More
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Webull offers Candel Therapeutics Inc stock information, including NASDAQ: CADL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CADL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CADL stock methods without spending real money on the virtual paper trading platform.